Search bioRxiv⌕ Search

Biology subjects

Dulan, C. N. M.

Publications and source records attributed to Dulan, C. N. M..

3 recordsLinked to original sources

Neuronal Grin2c expression and the cocaine engram: a medial prefrontal cortex substrate for conditioned place preference

Learned associations between drugs of abuse and drug-associated stimuli are thought to be encoded by physical alterations, termed engrams, within activity-dependent neuronal ensembles. However, the molecular mechanisms that support drug-memory engrams remain largely unknown. The goal of our study was to assess transcriptional alterations as candidate engrams within medial prefrontal cortex (mPFC) ensembles selectively activated by exposure to a cocaine-paired context following cocaine conditioned place preference (CPP). Using the immediate early gene Fos to identify strongly activated neurons, we found that mPFC was strongly activated by exposure to the cocaine-paired context, but not to the unpaired saline control context. We then used a combination of fluorescence activated cell sorting (FACS) and subsequent qPCR to identify gene targets upregulated in the Fos-positive mPFC ensemble neurons relative to the Fos-negative mPFC neurons following context re-exposure. Of the genes examined, the most strongly induced in the Fos-expressing neurons was Grin2c, which encodes the NR2C subunit of the NMDA receptor. We confirmed this finding using RNAscope in situ hybridization. To assess a causal role for Grin2c in cocaine-induced CPP, we used AAV-mediated, neuron-selective expression of Grin2c microRNA to knockdown Grin2c expression in mPFC neurons, which reduced cocaine CPP and facilitated CPP extinction over repeated tests. Our results indicate that neuronal Grin2c expression in the mPFC plays a role in associative learning underlying cocaine CPP. Future studies are needed to determine whether Grin2c expression plays a broader role within engrams underlying other forms of learning and memory.

neuroscience↗

A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure

Infection with Sudan virus (SUDV) is characterized by an aggressive disease course with case fatality rates between 40-100% and no approved vaccines or therapeutics. SUDV causes sporadic outbreaks in sub-Saharan Africa, including a recent outbreak in Uganda which has resulted in over 100 confirmed cases in one month. Prior vaccine and therapeutic efforts have historically prioritized Ebola virus (EBOV), leading to a significant gap in available treatments. Two vaccines, Erbevo(R) and Zabdeno(R)/Mvabea(R), are licensed for use against EBOV but are ineffective against SUDV. Recombinant adenovirus vector vaccines have been shown to be safe and effective against filoviruses, but efficacy depends on having low seroprevalence to the vector in the target human population. For this reason, and because of an excellent safety and immunogenicity profile, ChAd3 was selected as a superior vaccine vector. Here, a ChAd3 vaccine expressing the SUDV glycoprotein (GP) was evaluated for immunogenicity and efficacy in nonhuman primates. We demonstrate that a single dose of ChAd3-SUDV confers acute and durable protection against lethal SUDV challenge with a strong correlation between the SUDV GP-specific antibody titers and survival outcome. Additionally, we show that a bivalent ChAd3 vaccine encoding the GP from both EBOV and SUDV protects against both parenteral and aerosol lethal SUDV challenge. Our data indicate that the ChAd3-SUDV vaccine is a suitable candidate for a prophylactic vaccination strategy in regions at high risk of filovirus outbreaks. One Sentence Summary: A single-dose of ChAd3 vaccine protected macaques from lethal challenge with Sudan virus (SUDV) by parenteral and aerosol routes of exposure.

immunology↗

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron

SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to antibody neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-specific vaccines would enhance immunity and protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing antibody titers against D614G were 4760 and 270 reciprocal ID50 at week 6 (peak) and week 41 (pre-boost), respectively, and 320 and 110 for Omicron. Two weeks after boost, titers against D614G and Omicron increased to 5360 and 2980, respectively, for mRNA-1273 and 2670 and 1930 for mRNA-Omicron. Following either boost, 70-80% of spike-specific B cells were cross-reactive against both WA1 and Omicron. Significant and equivalent control of virus replication in lower airways was observed following either boost. Therefore, an Omicron boost may not provide greater immunity or protection compared to a boost with the current mRNA-1273 vaccine.

immunology↗